Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

NCT ID: NCT06337838

Last Updated: 2025-06-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-09
• Study Completion Date: 2027-06-30

Brief Summary

The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.

Detailed Description

Perioperative administration of TXA reduces bleeding risk in surgical patients. However, large clinical trials have excluded patients with advanced kidney disease, so the benefits remain uncertain in this population, and there is potential for harm. The benefit of desmopressin, which is purported to more directly address the defect of primary hemostasis believed important in severe kidney disease more directly than TXA, has not been examined in adequate randomized control trials (RCTs). Both medications are generic and have been available for many years. To convincingly test these medications in patients with severe kidney disease, large, global trials are required. This pilot-phase trial will 1) inform the feasibility and design of a large international trial to evaluate the efficacy and safety of TXA and desmopressin in patients with advanced kidney disease undergoing noncardiac surgery, 2) provide preliminary data regarding the efficacy and safety of TXA and desmopressin in people with advanced kidney disease having noncardiac surgery, and 3) provide pharmacokinetic data to inform dose selection.

Conditions

Chronic Kidney Diseases; Acute Kidney Injury; Bleeding; Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Prophylactic intravenous tranexamic acid and prophylactic intravenous desmopressin.

Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with estimated glomerular filtration rate (eGFR) <25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis.

Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin intervention group will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes.

Group Type: EXPERIMENTAL

Desmopressin Injectable Solution

Intervention Type: DRUG

Intravenous desmopressin, 20 mcg, single dose administration.

Tranexamic Acid Injectable Product

Intervention Type: DRUG

Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.

Prophylactic intravenous tranexamic acid and placebo.

Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with eGFR <25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis.

Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes.

Group Type: EXPERIMENTAL

Tranexamic Acid Injectable Product

Intervention Type: DRUG

Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.

Placebo

Intervention Type: OTHER

Intravenous 0.9% saline solution

Prophylactic intravenous desmopressin and placebo.

Within 20 minutes preceding anticipated skin incision, patients will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes. Patients will not receive prophylactic tranexamic acid.

Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group.

Group Type: EXPERIMENTAL

Desmopressin Injectable Solution

Intervention Type: DRUG

Intravenous desmopressin, 20 mcg, single dose administration.

Placebo

Intervention Type: OTHER

Intravenous 0.9% saline solution

Placebo and placebo.

Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group.

Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Intravenous 0.9% saline solution

Interventions

Desmopressin Injectable Solution

Intravenous desmopressin, 20 mcg, single dose administration.

Intervention Type: DRUG

Tranexamic Acid Injectable Product

Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.

Intervention Type: DRUG

Placebo

Intravenous 0.9% saline solution

Intervention Type: OTHER

Other Intervention Names

DDAVP; Cyklokapron

Eligibility Criteria

Inclusion Criteria

1. One of either:

1.1. eGFR <25 ml/min/1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;

2. Planned noncardiac surgery (elective, urgent, or emergency surgery);

3. Expected to require at least an overnight hospital admission after surgery;

4. Age ≥18 years; and

5. Informed consent is obtained to participate in the BRACKETS-Pilot Trial.

1. Included in the TXA factorial.

Exclusion Criteria

1. Undergoing cardiac surgery;

2. Undergoing intracranial neurosurgery;

3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;

4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;

5. Hypersensitivity or known allergy to TXA;

6. History of seizure disorder;

7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;

8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;

9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or

10. Previously enrolled in the BRACKETS-Pilot Trial.

Eligibility criteria specific to the desmopressin factorial component of trial

1. The hospital does not have access to desmopressin;

2. Planned use of prophylactic desmopressin;

3. Most recent serum sodium concentration < 130 mEq/L;

4. Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or

5. Hypersensitivity or known allergy to desmopressin.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Population Health Research Institute

OTHER

Sponsor Role: collaborator

Hamilton Health Sciences Corporation

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pavel Roshanov, MC,MSc,FRCPC

Role: PRINCIPAL_INVESTIGATOR

Western University

Locations

London Health Sciences Centre

London, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Ingrid Copland

Role: CONTACT

brackets@phri.ca

905-296-5754

Facility Contacts

Cadence Baker

Role: primary

cadence.baker@lhsc.on.ca

519-685-8500 ext. 34769

Other Identifiers

2024.BRACKETS-Pilot

Identifier Type: -

Identifier Source: org_study_id